High Efficacy of the Recombinant Zoster Vaccine for Herpes Z
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
A Study was conducted to examine the effectiveness of the recombinant zoster vaccine for preventing herpes zoster ophthalmicus in the general US population.

Individuals enrolled in the OptumLabs® Data Warehouse (OLDW) who were age-eligible for herpes zoster vaccination (more than 50 years old). Patients were required to have more than 365 days of continuous enrollment to be eligible.

Vaccination with the recombinant zoster vaccine was ascertained by CPT codes, and herpes zoster ophthalmicus was ascertained by ICD-10 codes. Cox proportional hazards regression models were used to estimate the hazard ratio of HZO associated with RZV, and inverse-probability weighting was used to control for confounding. Vaccine effectiveness was calculated from hazard ratios.

A total of 4842579 individuals were included in this study.
--177289 received two valid doses of RZV. The incidence rate of herpes zoster ophthalmicus was 25.5 cases per 100000 person-years in the vaccinated group compared to 76.7 in the unvaccinated group.
--The overall adjusted effectiveness of RZV against herpes zoster ophthalmicus was 89.1%.

In conclusion, RZV's efficacy against herpes zoster ophthalmicus in people aged 50 and up is strong in a real-world environment. The low vaccination rate, on the other hand, emphasizes the need for increased herpes zoster vaccination among the general public. Ophthalmologists can help qualified patients get vaccinated by suggesting vaccination.

Source: https://www.sciencedirect.com/science/article/abs/pii/S0161642021002876?dgcid=rss_sd_all